{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T18:50:04Z","timestamp":1795200604431,"version":"4.10.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In liver fibrosis, activated hepatic stellate cells are known to overexpress fibroblast activation protein. Here we report a targeted antifibrotic peptide-delivery system in which fibroblast activation protein, which is overexpressed in fibrotic regions of the liver, liberates the antifibrotic peptide melittin by cleaving a fibroblast activation protein-specific site in the peptide. The promelittin peptide is linked to pegylated and maleimide-functionalized liposomes, resulting in promelittin-modified liposomes. The promelittin-modified liposomes were effective in reducing the viability of activated hepatic stellate cells but not that of control cells. In three types of liver fibrosis mouse models, intravenously administered promelittin-modified liposomes significantly reduces fibrotic regions. In addition, in the bile duct ligation mouse model promelittin-modified liposome-treatment increases overall survival. Although this peptide-delivery concept was tested for liver fibrosis, it can potentially be adapted to other fibrotic diseases.<\/jats:p>","DOI":"10.1038\/s41467-022-29186-8","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T11:03:30Z","timestamp":1647860610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Jaiwoo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-2781","authenticated-orcid":false,"given":"Junho","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-2436","authenticated-orcid":false,"given":"Gayong","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0969-3339","authenticated-orcid":false,"given":"Yu-Kyoung","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"29186_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMra1504367","volume":"8","author":"PS Ge","year":"2016","unstructured":"Ge, P. S. & Runyon, B. A. Treatment of patients with cirrhosis. N. Engl. J. Med. 8, 767\u2013777 (2016).","journal-title":"N. Engl. J. Med."},{"key":"29186_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","volume":"121","author":"T Higashi","year":"2017","unstructured":"Higashi, T., Friedman, S. L. & Hoshida, Y. Hepatic stellate cells as key target in liver fibrosis. Adv. Drug. Deliv. Rev. 121, 27\u201342 (2017).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"29186_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coph.2019.09.006","volume":"49","author":"S Lemoinne","year":"2019","unstructured":"Lemoinne, S. & Friedman, S. L. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr. Opin. Pharmacol. 49, 60\u201370 (2019).","journal-title":"Curr. Opin. Pharmacol."},{"key":"29186_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jconrel.2019.04.022","volume":"303","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J. Control. Release 303, 77\u201390 (2019).","journal-title":"J. Control. Release"},{"key":"29186_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jconrel.2020.02.049","volume":"321","author":"JB Qiao","year":"2019","unstructured":"Qiao, J. B. et al. Hyperbranched lipoid-based lipid nanoparticles for bidirectional regulation of collagen accumulation in liver fibrosis. J. Control. Release 321, 629\u2013640 (2019).","journal-title":"J. Control. Release"},{"key":"29186_CR6","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1016\/j.bbamcr.2013.02.033","volume":"8","author":"ME Shaker","year":"2013","unstructured":"Shaker, M. E., Ghani, A., Shiha, G. E., Ibrahim, T. M. & Mehal, W. Z. Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases. Biochim. Biophys. Acta 8, 1992\u20132003 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"29186_CR7","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.3892\/mmr.2014.3048","volume":"4","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Celecoxib derivative OSU-03012 inhibits the Proliferation and activation of hepatic stellate cells by inducing cell senescence. Mol. Med. Rep. 4, 3021\u20133026 (2015).","journal-title":"Mol. Med. Rep."},{"key":"29186_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2741\/4706","volume":"24","author":"AJ Lay","year":"2019","unstructured":"Lay, A. J., Zhang, H. E., McCaughan, G. W. & Gorrell, M. D. Fibroblast activation protein in liver fibrosis. Front. Biosci. 24, 1\u201317 (2019).","journal-title":"Front. Biosci."},{"key":"29186_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan, D., Ashfaq-Khan, M., Yang, A. T. & Kim, Y. O. Liver fibrosis: Direct antifibrotic agents and targeted therapies. Matrix Biol. 68, 435\u2013451 (2018).","journal-title":"Matrix Biol."},{"key":"29186_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41181-019-0069-0","volume":"4","author":"T Lindner","year":"2019","unstructured":"Lindner, T. et al. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm. Chem. 4, 16 (2019).","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"29186_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1142\/S0192415X14500712","volume":"5","author":"SH Park","year":"2014","unstructured":"Park, S. H. et al. Melittin inhibits TGF-\u03b2-induced pro-fibrotic gene expression through the suppression of the TGF\u03b2RII-Smad, ERK1\/2, and JNK-mediated signaling pathway. Am. J. Chin. Med. 5, 1139\u20131152 (2014).","journal-title":"J. Chin. Med."},{"key":"29186_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules21050616","volume":"21","author":"G Lee","year":"2016","unstructured":"Lee, G. & Bae, H. Anti-inflammatory applications of melittin, a major component of bee venom: Detailed mechanism of action and adverse effects. Molecules 21, 1\u201310 (2016).","journal-title":"Molecules"},{"key":"29186_CR13","first-page":"446","volume":"16","author":"M Hu","year":"2021","unstructured":"Hu, M. et al. Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. Nat. Commun. 16, 446\u2013477 (2021).","journal-title":"Nat. Commun."},{"key":"29186_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19668-y","volume":"11","author":"H Xu","year":"2020","unstructured":"Xu, H. et al. AdipoR1\/AdipoR2 dual agonist recoversnonalcoholic steatohepatitis and related fibrosis viaendoplasmic reticulum-mitochondria axis. Nat. Commun. 11, 5807 (2020).","journal-title":"Nat. Commun."},{"key":"29186_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","volume":"2","author":"ML Boland","year":"2020","unstructured":"Boland, M. L. et al. Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function andlipogenesis. Nat. Metab. 2, 413\u2013431 (2020).","journal-title":"Nat. Metab."},{"key":"29186_CR16","doi-asserted-by":"crossref","unstructured":"Constandinou, C., Henderson, N. & Iredale, J. P. Fibrosis Research: Methods and Protocols (eds Varga, J., David A. Brenner, D. A. & Phan, S. H.) 237\u2013250 (Springer, 2005).","DOI":"10.1385\/1-59259-940-0:237"},{"key":"29186_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/hep4.1298","volume":"3","author":"B Ulmasov","year":"2018","unstructured":"Ulmasov, B. et al. An inhibitor of arginine-glycine-aspartate-binding integrins reverses fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatol. Commun. 3, 246\u2013261 (2018).","journal-title":"Hepatol. Commun."},{"key":"29186_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1034\/j.1600-0676.2002.01503.x","volume":"22","author":"MT Levy","year":"2002","unstructured":"Levy, M. T., McCaughan, G. W., Marinos, G. & Gorrell, M. D. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 22, 93\u2013101 (2002).","journal-title":"Liver"},{"key":"29186_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/hep.20853","volume":"42","author":"XM Wang","year":"2005","unstructured":"Wang, X. M., Yu, D. M. T., McCaughan, G. W. & Gorrell, M. D. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 42, 935\u2013945 (2005).","journal-title":"Hepatology"},{"key":"29186_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/icb.2016.116","volume":"95","author":"XM Wang","year":"2017","unstructured":"Wang, X. M. et al. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. Immunol. Cell. Biol. 95, 443\u2013453 (2017).","journal-title":"Immunol. Cell. Biol."},{"key":"29186_CR21","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1021\/acsnano.9b01383","volume":"13","author":"W Poon","year":"2019","unstructured":"Poon, W. et al. Elimination pathways of nanoparticles. ACS Nano 13, 5785\u20135798 (2019).","journal-title":"ACS Nano"},{"key":"29186_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/hepr.13040","volume":"48","author":"H Furuhashi","year":"2018","unstructured":"Furuhashi, H. et al. Vitamin A-coupled liposome system targeting free cholesterol accumulation in hepatic stellate cells offers a beneficial therapeutic strategy for liver fibrosis. Hepatology 48, 397\u2013407 (2018).","journal-title":"Hepatology"},{"key":"29186_CR23","doi-asserted-by":"publisher","first-page":"119616","DOI":"10.1016\/j.biomaterials.2019.119616","volume":"230","author":"QQ Fan","year":"2020","unstructured":"Fan, Q. Q. et al. Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials 230, 119616 (2020).","journal-title":"Biomaterials"},{"key":"29186_CR24","doi-asserted-by":"publisher","first-page":"1703393","DOI":"10.1002\/adma.201703393","volume":"30","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Multifunctional nanohybrid based on porous silicon nanoparticles, gold nanoparticles, and acetalated dextran for liver regeneration and acute liver failure theranostics. Adv. Funct. Mater. 30, 1703393 (2018).","journal-title":"Adv. Funct. Mater."},{"key":"29186_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99, 28\u201351 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"29186_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2018.05.032","volume":"283","author":"JB Qiao","year":"2018","unstructured":"Qiao, J. B. et al. Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis. J. Control. Release 283, 113\u2013125 (2018).","journal-title":"J. Control. Release"},{"key":"29186_CR27","doi-asserted-by":"publisher","first-page":"1706332","DOI":"10.1002\/adfm.201706332","volume":"28","author":"K Hayashi","year":"2018","unstructured":"Hayashi, K., Maruhashi, T., Sakamoto, W. & Yogo, T. Organic\u2013inorganic hybrid hollow nanoparticles suppress oxidative stress and repair damaged tissues for treatment of hepatic fibrosis. Adv. Funct. Mater. 28, 1706332 (2018).","journal-title":"Adv. Funct. Mater."},{"key":"29186_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09673-5","volume":"7","author":"L Wu","year":"2017","unstructured":"Wu, L. et al. Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-\u03b21\/Smads and PI3K\/Akt pathways. Sci. Rep. 7, 9289 (2017).","journal-title":"Sci. Rep."},{"key":"29186_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29024-2","volume":"8","author":"A Saha","year":"2018","unstructured":"Saha, A. et al. Development of nsP2 protease based cell free high throughput screening assay for evaluation of inhibitors against emerging Chikungunya virus. Sci. Rep. 8, 10831 (2018).","journal-title":"Sci. Rep."},{"key":"29186_CR30","doi-asserted-by":"publisher","first-page":"12748","DOI":"10.1039\/C5CC04905A","volume":"51","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Jiang, K., Zhu, J., Zhang, L. & Lin, H. A FRET-based carbon dot-MnO2 nanosheet architecture for glutathione sensing in human whole blood samples. Chem. Commun. 51, 12748\u201312751 (2015).","journal-title":"Chem. Commun."},{"key":"29186_CR31","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.3748\/wjg.v22.i48.10512","volume":"48","author":"CY Zhang","year":"2016","unstructured":"Zhang, C. Y., Yuan, W. G., He, P., Lei, J. H. & Wang, C. X. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks, and therapeutic targets. World J. Gastroenterol. 48, 10512\u201310522 (2016).","journal-title":"World J. Gastroenterol."},{"key":"29186_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00726-017-2490-6","volume":"50","author":"P Li","year":"2018","unstructured":"Li, P. & Wu, G. Roles of dietary glycine, proline, and hydroxyproline in collagen synthesis and animal growth. Amino Acids 50, 29\u201338 (2018).","journal-title":"Amino Acids"},{"key":"29186_CR33","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1017\/S1462399409000994","volume":"11","author":"SS Glaser","year":"2009","unstructured":"Glaser, S. S., Gaudio, E., Miller, T., Alvaro, D. & Alpini, G. Cholangiocyte proliferation and liver fibrosis. Expert. Rev. Mol. Med. 11, e7 (2009).","journal-title":"Expert. Rev. Mol. Med."},{"key":"29186_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen, X. & Song, E. Turning foes to friends: Targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99\u2013115 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"29186_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/prca.201300095","volume":"8","author":"EJ Hamson","year":"2014","unstructured":"Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O. & Gorrell, M. D. Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy. Proteom. Clin. Appl. 8, 454\u2013463 (2014).","journal-title":"Proteom. Clin. Appl."},{"key":"29186_CR36","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.15419\/bmrat.v6i6.549","volume":"6","author":"H Do","year":"2019","unstructured":"Do, H. et al. Recombinant human granulocyte colony-stimulating factor alleviates liver fibrosis in bile duct-ligated mice. Biomed. Res. Ther. 6, 3222\u20133232 (2019).","journal-title":"Biomed. Res. Ther."},{"key":"29186_CR37","doi-asserted-by":"publisher","first-page":"165958","DOI":"10.1016\/j.bbadis.2020.165958","volume":"1886","author":"B Sanjel","year":"2020","unstructured":"Sanjel, B. & Shim, W. S. Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. Biochim. Biophys. Acta Mol. Basis Dis. 1886, 165958 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"29186_CR38","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1002\/adsc.201200641","volume":"354","author":"T Pesnot","year":"2012","unstructured":"Pesnot, T., Gershater, M. C., Ward, J. M. & Hailes, H. C. The catalytic potential of coptis japonica NCS2 revealed development and utilisation of a fluorescamine-based assay. Adv. Synth. Catal. 354, 2997\u20133008 (2012).","journal-title":"Adv. Synth. Catal."},{"key":"29186_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jconrel.2019.02.012","volume":"298","author":"G Shim","year":"2019","unstructured":"Shim, G. et al. Sequential activation of anticancer therapy triggered by tumor microenvironment-selective imaging. J. Control. Release 298, 110\u2013119 (2019).","journal-title":"J. Control. Release"},{"key":"29186_CR40","first-page":"e52438","volume":"96","author":"CG Tag","year":"2015","unstructured":"Tag, C. G. et al. Bile duct ligation in mice: Induction of inflammatory liver injury and fibrosis by obstructive cholestasis. J. Vis. Exp. 96, e52438 (2015).","journal-title":"J. Vis. Exp."},{"key":"29186_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/iep.12008","volume":"94","author":"M Matsumoto","year":"2013","unstructured":"Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in non\u2010alcoholic steatohepatitis. Int. J. Exp. Pathol. 94, 93\u2013103 (2013).","journal-title":"Int. J. Exp. Pathol."},{"key":"29186_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nprot.2015.017","volume":"10","author":"I Mederacke","year":"2015","unstructured":"Mederacke, I., Dapito, D. H., Aff\u00f2, S., Uchinami, H. & Schwabe, R. H. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat. Protoc. 10, 305\u2013315 (2015).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29186-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:43:33Z","timestamp":1669308213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["29186"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-29186-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"15 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1516"}}